Biogen Idec, Inc. (Massachusetts) to Present Extensive New Data From Its Robust Multiple Sclerosis Portfolio at ECTRIMS
WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will present 58 data sets from the company’s multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5.
Help employers find you! Check out all the jobs and post your resume.